Unpacking Key Data from ASH 2024 - Episode 9
Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
Panelists discuss how the updated results from Arm 8 of the Epcore NHL-2 trial on Fixed-Duration Epcoritamab + R-Mini-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) ineligible for full-dose R-CHOP may influence treatment selection by offering a potentially effective alternative for this patient population
Video content above is prompted by the following:
Fixed-Duration Epcoritamab+R-Mini-CHOP
The updated results from Arm 8 of the Epcore NHL-2 trial (L. Leslie, ASH 2024, abstract #3106) evaluate the combination of fixed-duration epcoritamab with R-Mini-CHOP in patients with previously untreated DLBCL who are ineligible for full-dose R-CHOP therapy. The trial aimed to assess the safety, efficacy, and feasibility of this regimen in this patient population.
Key Findings:
- The combination of epcoritamab (a bispecific antibody targeting CD3 and CD20) and R-Mini-CHOP demonstrated promising efficacy in terms of overall response rates and progression-free survival for patients unable to tolerate the standard R-CHOP regimen.
- Safety: The treatment regimen was well tolerated, with manageable toxicities. The reduced intensity of R-Mini-CHOP was particularly beneficial for patients who could not tolerate full-dose R-CHOP due to age or comorbidities.
- Efficacy: The combination showed high response rates, with many patients achieving complete responses, suggesting that this regimen could be a viable alternative for patients with DLBCL with specific contraindications to full-dose chemotherapy.
Implications for Treatment Selection:
- The findings may offer an alternative treatment option for older or frail patients with DLBCL who are not candidates for full-dose R-CHOP, providing a fixed-duration therapy with a favorable safety profile.
- Physicians may consider epcoritamab + R-Mini-CHOP as a potential treatment strategy for patients who cannot tolerate more intensive regimens, potentially improving outcomes in this underserved population.
- Further long-term follow-up is necessary to confirm the durability of responses and the potential for improved survival outcomes.
In conclusion, this regimen could represent a meaningful treatment advancement, expanding therapeutic options for patients with untreated DLBCL who are ineligible for full-dose R-CHOP.
Related Content:
